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Abstract
Background: Recent years have seen standardization of the anatomic definitions of pancreatic adenocarcinoma,
and increasing utilization of neoadjuvant therapy (NAT). The aim of the current review was to summarize the
evidence for NAT in pancreatic adenocarcinoma since 2009, when consensus criteria for resectable (R), borderline
resectable (BR), and locally advanced (LA) disease were endorsed.
Methods: PubMed search was undertaken along with extensive backward search of the references of published
articles to identify studies utilizing NAT for pancreatic adenocarcinoma. Abstracts from ASCO-GI 2014 and 2015
were also searched.
Results: A total of 96 studies including 5520 patients were included in the final quantitative synthesis. Pooled
estimates revealed 36% grade ≥ 3 toxicities, 5% biliary complications, 21% hospitalization rate and low mortality
(0%, range 0–16%) during NAT. The majority of patients (59%) had stable disease. On an intention-to-treat
basis, R0-resection rates varied from 63% among R patients to 23% among LA patients. R0 rates were > 80%
among all patients who were resected after NAT. Among R and BR patients who underwent resection after
NAT, median OS was 30 and 27.4 months, respectively.
Conclusions: The current study summarizes the recent literature for NAT in pancreatic adenocarcinoma and
demonstrates improving outcomes after NAT compared to those historically associated with a surgery-first
approach for pancreatic adenocarcinoma.
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Background
Pancreatic cancer is one of the leading causes of cancer-
related mortality with an estimated 53,670 new cases
and an estimated 43,090 deaths in 2017 [1]. The overall
survival for all patients with pancreatic cancer remains
dismal—approximately 7% at 5 years [2–4]. Most of the
patients present with metastatic disease. Even for those
without metastatic disease, surgical treatment can be
complex given the local extent of the tumor, with only
10–20% being candidates for upfront surgery, and these
operable patients may experience 5 year survival of 10–
30% [3]. Recent years have seen several advances in the
management of pancreatic adenocarcinoma. In 2009, an
expert consensus statement defined the criteria (based
on vascular involvement assessed by preoperative
imaging) based on which non-metastatic pancreatic
adenocarcinoma is broadly categorized into three cat-
egories: resectable, borderline resectable and locally
advanced disease [5–7]. Although subtle differences re-
main between the different consensus criteria (NCCN,
Intergroup, AHPBA/SSO, etc.) based on the extent of
vascular involvement, these definitions have made the
anatomic classification of pancreatic adenocarcinoma
more uniform and have made cross study comparisons
more reliable.
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Since 1997, gemcitabine has been the reference drug for
advanced pancreatic cancer after a randomized trial
reported a marginal improvement in overall survival and
improved quality of life over 5-FU alone (5.6 vs
4.4 months, p = 0.0025) [8]. Systemic therapy for ad-
vanced pancreatic adenocarcinoma (including metastatic
disease) has improved with the availability of more effect-
ive chemotherapeutic regimens such as FOLFIRINOX
(median OS 11.1 months, RR 31.6%) and gemcitabine with
nab-paclitaxel (median OS 8.5 months, RR 23%). [9, 10]
Advances in the chemotherapeutic treatment of meta-
static pancreatic adenocarcinoma have been extrapolated
to other potentially resectable categories of pancreatic
adenocarcinoma [9–15]. More aggressive multimodality
treatments have been employed for the management of
resectable and borderline resectable tumors in addition to
locally advanced tumors [11–13]. Imaging modalities
(pancreas protocol CT scan) and radiation delivery tech-
niques such as IMRT and SBRT have evolved which have
further advanced the care of these patients.
Neoadjuvant treatment (NAT) strategies are increas-
ingly being employed for borderline resectable and
resectable tumors [11–13]. These strategies lead to early
initiation of systemic therapy in these patients in con-
trast to a surgery first approach where up to half of the
patients may not receive adjuvant therapy due to post-
operative complications or decline in functional status
[16–18]. Theoretically, the neoadjuvant approach down-
stages nodal disease, increases the rate of margin nega-
tive resection, and also helps to identify patients at risk
of early disease progression [19, 20].
Although previous authors have elegantly reviewed the
literature on the subject, recent years have seen several
advancements as mentioned above [21–23]. The aim of
Fig. 1 PRISMA Study flow diagram depicting search strategy, screening, selection, and exclusion criteria
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the current study was to perform a systematic review of
the literature since 2009 (the year in which the expert
consensus criteria were endorsed by several surgical
societies) and summarize the current landscape for the
role and outcomes of neoadjuvant therapy in the treat-
ment of all non-metastatic anatomic subcategories of
pancreatic cancer, i.e., resectable, borderline resectable
and locally advanced unresectable disease.
Methods
Search strategy
Articles in PubMed database from January, 2009 to May
2015 were searched using the key words “Neoadjuvant”
[All Fields] AND “Pancreatic cancer” [All Fields]. Such a
search strategy was chosen to capture any English
language article reporting on the neoadjuvant treatment
of pancreatic cancer. PubMed database was used as it
remains one of the most widely used medical literature
resources, and only indexes peer-reviewed biomedical
literature [24].
Inclusion and exclusion criteria
Title and abstract review was performed for 279 articles to
identify relevant articles. Studies reporting the use of
neoadjuvant therapies in non-metastatic patients with
pancreatic adenocarcinoma were selected for full text
review. Case reports, letters, and review articles were
excluded. The search strategy is depicted in detail in Fig. 1.
Prospective or retrospective studies of patients with pan-
creatic adenocarcinoma treated with neoadjuvant therap-
ies (including chemotherapy, chemoradiotherapy or
radiotherapy) were evaluated. All phase 1–2 clinical trials,
cohort studies and case series were included. Only studies
of patients with pancreatic adenocarcinoma were
included. Studies reporting combined outcomes of peri-
ampullary tumors were excluded. All identified case re-
ports and studies with identical patient cohorts over a
similar time period were excluded. A backward search was
also performed using bibliographies of relevant articles
and review articles to ensure a comprehensive search.
Additionally, abstracts from American Society of Clinical
Oncology, Gastrointestinal Cancer Symposium (ASCO GI)
under the categories “Cancers of the Pancreas, Small Bowel,
and Hepatobiliary Tract” AND “Multidisciplinary Treat-
ment” were reviewed. Title review was performed for 302
abstracts of which 38 were further selected for abstract and
review of online posters. Fifteen relevant abstracts were
included in the qualitative and quantitative synthesis.
Search for conference abstracts was limited as there may be
differences in the data presented in the initial abstract and
final publication [25].
Figure 1 depicts the study flow diagram. Preferred
Reporting Items for Systematic Reviews and Meta-
analysis (PRISMA) guidelines were followed with regards
to reporting of results [26]. A checklist has been
included in the supplementary files.
Data extraction and definitions
Data were extracted from the selected articles by the
first and second author (M.D. and G.M.). Inconsistencies
were resolved by discussion and consulting the corre-
sponding author when needed. Data extracted included
first author, article type, journal, study methodology,
type of neoadjuvant therapy, regimen details, type of tu-
mors (resectable, borderline resectable, locally advanced
or combinations thereof ), number of patients, radiologic
response (complete response, partial response, stable dis-
ease, progression), overall and grade 3 toxicity of neoad-
juvant therapy, grade 3 toxicities of specific types (i.e.,
anemia, leukopenia, lymphopenia, neutropenia, febrile
neutropenia, thrombocytopenia, fatigue, nausea/vomit-
ing, diarrhea, anorexia, weight loss, biliary obstruction/
cholangitis, gastritis/duodenitis/GI bleed), readmission
rates, mortality associated with neoadjuvant therapy,
pathologic response, overall survival, and progression-
free survival.
For the calculation of toxicities, radiologic response,
and resection rates only studies reporting the outcomes
of all patients who underwent neoadjuvant therapy
followed by restaging were included. Studies reporting
the outcomes of only patients resected after neoadjuvant
therapy were included in the calculation of postoperative
morbidity and mortality. For studies reporting on
combination of various anatomic categories, e.g., border-
line resectable and locally advanced, data were recorded
separately wherever feasible. When different anatomic
subcategories could not be used separately for data ex-
trapolation due to reporting of combined outcomes such
studies were listed under BR + LA (borderline resectable
and locally advanced patients) and R + BR + LA (resect-
able, borderline resectable, and locally advanced). Only
BR + LA category results were reported given the
limited number of patients in the other combined
categories. Similarly, for double-armed studies or retro-
spective studies reporting on two different treatment
types, data were recorded separately wherever feasible.
The data extraction process was performed twice to en-
sure the accuracy of the data. Data were also recorded
on vascular resections especially for BR and LA categor-
ies, dose of radiation therapy, age and gender of the
study population, number of cycles of chemotherapy,
adjuvant therapy, and follow up to assess the quality of
the studies. However, given lack of consensus to assess
the quality of non-randomized clinical trials, all studies
were included based on completeness of data and inclu-
sion/exclusion criteria.
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Statistical methods
Summary statistics are reported as total and percentages
for categorical variables vs mean or median with corre-
sponding standard deviation or ranges, respectively, for
continuous variables. Meta-analysis was performed using
STATA 14.2 statistical software (StataCorp, 4905 Lakeway
Drive, College Station, Texas). Meta-analysis of propor-
tions strategy using the command “metaprop” was uti-
lized. Pooled estimates of proportions with corresponding
Table 1 Summary of studies included in the quantitative analysis
N %
Total number of studies included 96
Original articles 82 85.4
Abstracts 14 14.6
Year of publication
2009 6 6.3
2010 7 7.3
2011 8 8.3
2012 12 12.5
2013 17 17.7
2014 29 30.2
2015 17 17.7
Global distribution of location of institutions of selected studies
North America 54 56.3
Europe 21 21.9
Asia 18 18.7
Australia/Africa/South America (1 each) 3 3.1
Single vs multi-institutional
Single institution 83 86.5
Multi-institutional 13 13.5
Type of study
Retrospective series 54 56.3
Phase 2 studies 22 22.9
Prospective series 11 11.5
Phase 1 studies 5 5.2
Phase 1/2 studies 3 3.1
Phase 3 studies 1 1
Criteria for resectability
NCCN/AHPBA/SSO/SSAT consensus 38 39.6
MD Anderson 8 8.3
Other 29 30.2
Not mentioned 21 21.9
Number of studies of each local/anatomical stage
Resectable 18 18.8
Borderline resectable (BR) 15 15.6
Locally advanced unresectable (LA) 29 30.2
R + BR 5 5.2
BR + LA 24 25
R + BR + LA 5 5.2
Number of patients in each anatomical stage
Resectable 1056 19.1
Borderline resectable (BR) 935 16.9
Locally advanced unresectable (LA) 1840 33.3
R + BR 202 3.7
BR + LA 1014 18.4
Table 1 Summary of studies included in the quantitative analysis
(Continued)
R + BR + LA 473 8.6
Criteria for of radiology response assessment
RECIST 48 50
WHO 5 5.2
Other 2 2.1
Not mentioned 41 42.7
Criteria for toxicity assessment
NCI CTCAE 43 44.8
WHO 5 5.2
RTOG 2 2.1
Not mentioned/not applicable 46 47.9
Type of neoadjuvant therapy
Chemoradiotherapy 33 34.4
Chemotherapy alone 20 20.8
Chemotherapy with chemoradiation 41 42.7
Radiation alone 2 2.1
Chemotherapy drugs
Monotherapy (Gem/5FU/Cape/UFT/Cis) 26 27.1
FOLFIRINOX 20 20.8
Gemcitabine + oxaliplatin* 8 8.3
Gemcitabine or 5FU + cisplatin 7 7.3
Gemcitabine + Docetaxel 3 3.1
GTX (gemcitabine, taxane, capecitabine) 6 6.3
Gem + biologic (bevacizumab, cetuximab) 3 3.1
Gem + S1 5 5.2
Gem + Nab-paclitaxel 2 2.1
5FU + cisplatin + interferon 1 1
Multiple 11 11.5
Not mentioned 2 2.1
None 2 2.1
Radiotherapy
Yes 76 79.2
No 20 20.8
*Includes one study with gemcitabine + oxaliplatin + cetuximab
R resectable, BR borderline resectable, LA locally advanced, Gem Gemcitabine,
Cape capecitabine, 5FU 5 Fluorouracil, UFT uracil/tegafur
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95% confidence intervals were reported and calculated
using Freeman-turkey double arcsine transformation [27].
Random effects model was used due to our suspicion of
heterogeneity among different studies. Heterogeneity was
explored using the chi-squared test with a significance
level of p = 0.05. I2 was calculated to further quantify
heterogeneity. Publication bias was explored using funnel
plots and symmetry of the funnel plot was analyzed using
visual inspection and Begg’s tests to rule out any bias from
the studies with small patient samples [28, 29]. Addition-
ally, subset analyses were used wherever feasible. The
weighted aggregated median survival times were generated
using SAS software, Version 9.4 (SAS Institute Inc., Cary,
NC, USA). Since most studies only supplied median survival
times and no additional information, i.e., patients at risk,
confidence intervals, hazard ratios, etc. were consistently
Fig. 2 Summary of outcomes after neoadjuvant therapy among resectable, borderline resectable, and locally advanced unresectable patients with
pancreatic adenocarcinoma
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available, we used the method described by Gillen et al. to
weight and aggregate the median survival times [23]. Briefly,
wi denotes the weight of an individual study which is calcu-
lated as n/N where n is the number of study participants,
and N is the total number of evaluable patients within a
stratum. If mi (i= 1,…, k) represents the median survival
time of an individual study within a stratum, then a weighted
estimate of the median survival of the stratum (ms) can be
calculated as follows.
ms ¼
Pk
i¼1
wi
mi
 −1
where ∑wi = 1.
Confidence intervals cannot be computed using the
method described by Gillen et al. [23]. Instead, Gillen et
al. recommend reporting the minimum and maximum
median survival times. [23]
Results
Patient and study characteristics
A total of 96 studies [30–125] including 82 original
articles and 14 abstracts including 5520 patients, were
selected for qualitative and quantitative synthesis. These
include 1056 patients with resectable tumors, 935 with
borderline resectable tumors, and 1840 with locally
advanced unresectable tumors, with an additional 1689
patients in overlapping categories. Most of the studies
were retrospective series but 22 phase II studies were
also included in the current analysis. Sixty-five percent
of the included studies were from 2013 to 2015. Majority
(78.1%) of the studies mentioned resectability criteria.
Majority of the included studies were single institutional
(86.5%) and majority were from institutions located in
North America and Europe (78.2%). Chemotherapy
alone was used in 20 (20.8%) studies, chemoradiotherapy
in 33(34.4%) studies, chemotherapy with chemoradiation
was used in 41 (42.7%), and radiation alone was used in
2 (2.1%) studies. Type of chemotherapy agent utilized
included FOLFIRINOX in 810 patients, GTX in 410
patients, single drug (gemcitabine/5FU/capecitabine) in
1521 patients, two-drug regimen (gem + cisplatin/nab-
paclitaxel/oxaliplatin/bevacizumab/docetaxel/S1) in 1113
patients or three drug combinations other than FOLFIR-
INOX or GTX in 60 patients. Studies with 1198 patients
described use of multiple regimes whereas 222 patients
had RT alone and in 186 patients chemotherapy agent
was not described. Table 1 provides a summary of
major characteristics of the included studies and
Additional file 1: Table S1 provides details on all the
included studies. Figure 2 provides a snapshot and
Tables 1 through 5 provide details of results which
are also elaborated below.
Toxicity
Only grade ≥ 3 toxicities were analyzed. Data regarding
any form of grade ≥ 3 toxicity were available in 55 of the
96 studies. Details regarding toxicity are summarized in
Table 2. Briefly, overall grade ≥ 3 toxicity was seen in
36% of the patients (95% CI 27–45%). Hematologic
grade ≥ 3 toxicity was more common than non-
hematologic grade ≥ 3 toxicity (25 vs 16%). One-fifth of
all patients receiving therapy were hospitalized during
the neoadjuvant therapy. Over 90% of the patients were
able to complete majority of the neoadjuvant treatment
(not considering dose reductions). Most studies reported
a mortality rate of 0% (95% CI 0–1%). Funnel plots for
overall grade ≥ 3 toxicity are reported in Additional file 3:
Figure S1. No statistically significant publication bias
was noted using Begg’s test (p = 0.572) and Egger’s test
(p = 0.293).
A subset analysis was performed for overall grade ≥ 3
toxicities for studies utilizing NCI CTCAE criteria.
Again overall grade ≥ 3 toxicity was noted in 36% of the
patients (95% CI 24–48%). Pooled estimates for studies
utilizing NCI CTCAE criteria were similar to those
obtained for all studies reporting overall grade ≥ 3 toxic-
ities. Figure 3 depicts the forest plot for overall grade ≥ 3
toxicities in the studies utilizing NCI CTCAE criteria.
Table 2 Grade 3 or higher toxicities, readmission rates and
mortality during the neoadjuvant treatment of patients with
pancreatic adenocarcinoma
Grade 3 or higher
toxicities
Number of
studies
reporting
the studied
outcome
% 95% confidence
interval
Overall 39 36% 27–45%
Hematologic 16 25% 14–38%
Anemia 33 4% 3–6%
Leukopenia 26 25% 18–32%
Lymphopenia 8 13% 4–24%
Neutropenia 38 23% 17–29%
Febrile neutropenia 17 3% 1–5%
Thrombocytopenia 41 7% 5–10%
Non hematologic 17 16% 7–27%
Nausea/vomiting 40 7% 4–10%
Diarrhea 38 4% 2–6%
Anorexia 19 3% 1–6%
Fatigue 26 4% 1–7%
Biliary obstruction/cholangitis 22 5% 3–7%
GI bleed, gastritis, or duodenitis, 14 3% 1–7%
Hospitalization rate 15 21% 14–27%
% of patients completing
neoadjuvant therapy
42 90% 87%–93%
Mortality 48 0% 0–1%
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Radiologic response
The results for radiologic response by broad categories
(disease control and progression) are outlined in Fig. 2,
whereas the complete details of radiologic response
(complete response, partial response, stable disease and
progressive disease) are highlighted in Table 3. Tumor
response was evaluated in 61 studies prior to resection,
however not all studies mentioned all response categor-
ies including complete response, partial response, stable
disease and progressive disease. As previously reported,
the incidence of complete response was between 0–1%.
Overall partial response was seen in 20% (95% CI 16–
25%). Most patients had stable disease 59% (95% CI 54–
65%). Overall progressive disease during neoadjuvant
therapy was noted in 16% (95% CI 12–20%) of patients.
In patients with resectable tumors, there were no
complete radiologic responses. Partial response was seen
in 11% of patients and majority (77%) had stable disease.
Progression was noted in 11% of the patients. In patients
with borderline resectable tumors, 20% had partial
response, 56% had stable disease and 19% progressed
during therapy. In patients with locally advanced disease,
1% had complete response, 28% had partial response,
48% stable disease, and 20% experienced progression
after neoadjuvant therapy. Stable disease was the
predominant pattern across all disease categories. Funnel
plots are depicted in Additional file 3: Figures. S2 thru
S4. Although funnel plots were found to be symmetric
on visual inspection, small study effects were more pro-
nounced for stable disease (Begg’s test p = 1, Egger’s test
p = 0.02) and progressive disease analyses (Begg’s test
p = 0.135, Egger’s test p = 0.033).
Subset analysis was performed for studies utilizing the
NCCN/AHPBA/SSO/SSAT criteria for resectability and
RECIST criteria for radiologic response (Figs. 4, 5, and
6). Similar to the results of all studies, subset analysis
revealed an overall complete response of 0% (0–1%)
including 0% (95% CI 0–0%) for resectable disease, 1%
(95% CI 0–4%) for borderline resectable and 1% (95% CI
0–3%) for locally advanced disease. Similarly, rates of
partial response were 14% (95% CI 11–19%) for resect-
able, 30% (95% CI 18% - 43%) for borderline resectable
Fig. 3 Forest plot depicting pooled estimates for overall grade ≥ 3 toxicities among studies utilizing NCI CTCAE criteria for toxicity assessment
during neoadjuvant therapy
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and 24% (95% CI 11–40%) for locally advanced patients.
Rates of stable disease were 81% (95% CI 76–85%), 55%
(95% CI 43–66%) and 55% (95% CI 34–75%) for resect-
able, borderline resectable, and locally advanced patients,
respectively. Rates of progressive disease varied, being
3% (95% CI 1–5%) for resectable disease, 12% (95% CI
7–18%) for borderline resectable, and 21% (95% CI 5–
42%) for locally advanced patients.
Exploration and resection rates
Figure 2 provides a summary and Table 4 provides
details of the surgical resection rates after neoadjuvant
therapy for pancreatic adenocarcinoma. Exploration and
resection rates were calculated on an intention-to-treat
basis, i.e., denominator included all patients who under-
went neoadjuvant therapy. These data were available for
most included studies. Exploration rates varied by the
disease category, i.e., resectable (86%), borderline resect-
able (77%) and locally advanced (32%). As expected, the
highest resection rates were noted for resectable patients
(76%), followed by borderline resectable (69%), and locally
advanced disease (26%). R0 resection rates were 63% for
resectable patients, 54% for borderline resectable, and 23%
for locally advanced disease on an intention-to-treat basis.
For all patients in all categories who were selected for
resection after neoadjuvant therapy, 85% had R0 resection.
Funnel plots are depicted in Additional file 3:Figures S5
thru S6. No significant small study effects were noted for
exploration (Begg’s test p = 0.234, Egger’s test p = 0.085)
and resection rates (Begg’s test p = 0.528, Egger’s test
p = 0.457).
Subset analysis for resection rates was performed for
studies utilizing the NCCN/AHPBA/SSO/SSAT criteria
for resectability (Fig 7). Resection rates on an intention
to treat basis were 80% for resectable patients (95% CI
53–98%), 70% for borderline resectable patients (95% CI
59–80%) and 32% for locally advanced patients (95% CI
19–46%).
Pathologic response
Figure 2 provides a summary and Additional file 2: Table S2
provides details of the pathologic responses after neoadju-
vant therapy. Pathologic grading of the tumor response was
available in 36 studies. The Evans grading system was used
in 16 studies. Regardless of the pathologic grading system
used, if complete pathologic responses were reported, they
were counted as grade 4 Evans responses and > 90% tumor
destruction was considered grade 3. For further analysis we
focused on the Evans grading system for response to neoad-
juvant therapy. Grade 2a (37%) or 2b (27%) were the
predominant histopathologic response types. Funnel plots
were not generated given small number of studies. There is
risk of bias with these calculations given the limitation of
small number of studies which reported Evans criteria.
Surgical morbidity and mortality
The overall morbidity was calculated for all patients
undergoing exploration whereas grade 3 or higher
morbidity was calculated for patients who underwent re-
section. Twenty eight studies reported the morbidity
rates and 41 studies reported the perioperative mortality
rates. Overall morbidity, grade 3 or higher morbidity
and perioperative mortality rates were 39% (95% CI 33–
45%), 18% (13–23%) and 1% (0–2%), respectively. Funnel
plots are depicted in Additional file 3: Figures S7 and S8.
No significant small study effects were noted (Begg’s test
and Egger’s test > 0.05).
Overall survival
A meta-analysis of the median OS and PFS was per-
formed using the strategy proposed by Gillen et al. [23]
Fig. 2 provides a summary and Table 5 provides details
of median OS for all patients stratified by the extent of
the disease and resection status. Pooled median OS in
studies with single-agent chemotherapy (gemcitabine, 5-
Table 3 Radiologic response after completion of neoadjuvant
therapy for patients with pancreatic adenocarcinoma
Radiologic response
Complete
response
Partial
response
Stable
disease
Progressive
disease
Resectable 0% 11% 77% 11%
[0–0%] [8–16%] [62–89%] [4–19%]
I2 = 0% I2 = 10.6% I2 = 85.12% I2 = 82.31%
(n = 8) (n = 8) (n = 9) (n = 11)
Borderline
resectable
1% 20% 56% 19%
[0–4%] [8–35%] [47–64%] [11–28%]
I2 = 52.03% I2 = 84.28% I2 = 33.25% I2 = 58.95%
(n = 8) (n = 8) (n = 8) (n = 9)
Locally advanced 1% 28% 48% 20%
[0–3%] [21–35%] [38–58%] [13–29%]
I2 = 57.02% I2 = 82.61% I2 = 88.09% I2 = 89.43%
(n = 17) (n = 19) (n = 17) (n = 18)
BR + LA 0% 20% 59% 14%
[0–1%] [11–31%] [49–69%] [8–22%]
I2 = 7.57% I2 = 84.70% I2 = 76.89% I2 = 72.59%
(n = 16) (n = 16) (n = 16) (n = 16)
All patients 0% 20% 59% 16%
[0–1%] [16–25%] [54–65%] [12–20%]
I2 = 38.25% I2 = 81.52% I2 = 85.12% I2 = 82.84%
(n = 52) (n = 56) (n = 56) (n = 62)
Values in [] reflect the 95% confidence interval. I2 is a quantitative indicator of
heterogeneity among the studies, and n refers to the number of studies
reporting the outcomes
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fluorouracil, or capecitabine) was 14.7 months (range
9.1–47 months). Studies with two drug regimens were
noted to have a pooled median OS of 16.1 months
(range 7.3–45 months). Pooled median OS was longest
in the studies utilizing FOLFIRINOX with median OS of
22.1 months (range 16.7–34 months) followed by GTX
(Gemcitabine, Taxane, Capecitabine) at 19.4 months
(range 15.6–25 months). Funnel plots were not gener-
ated as a different methodology as previously reported
by Gillen et al. was utilized.
Discussion
With the expert consensus statement guidelines released
in 2009, providing a uniform foundation was created for
categorizing non-metastatic pancreatic adenocarcinoma
into resectable, borderline resectable, and locally advanced
disease. Given the overall poor prognosis of pancreatic
adenocarcinoma, neoadjuvant therapy is being increas-
ingly studied in the treatment of pancreatic adenocarcin-
oma across all anatomic categories including resectable,
borderline resectable, and locally advanced disease. In
recent years, we have seen several advancements with the
introduction of newer chemotherapeutic regimens (FOL-
FIRNOX and gemcitabine-nab-paclitaxel) and their inte-
gration into the neoadjuvant therapeutic paradigm.
The current review was undertaken to summarize the
outcomes for neoadjuvant therapy in pancreatic adeno-
carcinoma post-2009 which marks the release of the
consensus statements as well as the introduction of
newer neoadjuvant regimens. Integrating the breakdown
of pancreatic adenocarcinoma by anatomic category with
chemotherapy and surgical characteristics, the current
analyses includes 5520 patients from 96 studies. The
resulting data formulate a perspective on critical
outcomes including toxicities, responses, surgical, and
survival characteristics that can help guide patients and
physicians.
One concern of neoadjuvant therapy is that possible
toxicities might contribute to patient morbidity or
mortality. Grade ≥ 3 toxicities were seen in 36% of pa-
tients with a higher incidence of grade ≥ 3 hematologic
(25%) than non-hematologic toxicity (16%); however,
mortality during neoadjuvant therapy was low (95% CI
0–1%). The hospitalization rate during neoadjuvant ther-
apy was 21%. Our data suggest that these toxicities were
manageable since majority of patients (91%) were able to
complete neoadjuvant therapy as reported in 42 studies
(not considering dose modifications).
Neoadjuvant therapy remains most controversial for
patients with resectable pancreatic adenocarcinoma.
Fig. 4 Forest plots depicting pooled estimates for partial response at the time of restaging during or after neoadjuvant therapy. Only studies
utilizing NCCN or AHBPA/SSO/SSAT criteria were included in the forest plot
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Critics of the neoadjuvant approach have cited disease
progression, patient anxiety, and lack of proven benefit
of neoadjuvant therapy in patients with resectable
disease, whereas the proponents propose that neoadju-
vant therapy allows testing of tumor biology and spares
unnecessary surgery in patients who are destined to
develop rapidly progressive metastatic disease in the
immediate post-operative period. Stable disease remains
the predominant radiologic response after neoadjuvant
therapy. Progression was seen in a minority of patients
(16%) overall and in an even smaller proportion of
patients with resectable disease (11%). Surgical morbid-
ity and mortality after neoadjuvant therapy remain
acceptable with grade 3 or higher morbidity of 18% and
mortality of 1%. These are comparable to morbidity and
mortality after upfront resection. These data suggest that
progression during neoadjuvant therapy is rare and neo-
adjuvant therapy does not increase morbidity or mortal-
ity after surgery.
Although the main goal of any neoadjuvant strategy is
to prolong survival, another goal is to improve R0 resec-
tion, as positive resection margins have been shown to be
associated with worse survival [126–128]. Previous studies
of adjuvant therapy have reported an R1 resection rate of
24–42% [126, 127, 129, 130] whereas margin positive rate
has been < 10% in previous trials of neoadjuvant therapy
in selected centers [131, 132]. In the current study, for
patients (all disease categories) who were explored after
neoadjuvant therapy, over 80% of the patients had R0
resection. Importantly, patients with resectable disease
undergoing resection after the receipt of neoadjuvant ther-
apy have high likelihood of margin negative resection with
an improved estimated median survival of up to
30 months. Additionally, one could argue that R0 resec-
tion rate of 63% on an intention to treat basis may seem
low—this is in par with previous surgical series reporting
an R1 resection rate of >30% including ESPAC 3 (R1
rate = 35%) [126, 129, 130]. These data suggest that
neoadjuvant therapy increases the likelihood of R0 resec-
tion among all anatomic subcategories of pancreatic
adenocarcinoma.
In the current review, median OS for all patients with
resectable disease who underwent neoadjuvant therapy
was 18 months. Previous trials of adjuvant therapy have
reported a median OS of approximately 20–23 months
[129, 130, 133, 134]. However, the results are not
Fig. 5 Forest plots depicting pooled estimates for stable disease at the time of restaging during or after neoadjuvant therapy. Only studies
utilizing NCCN or AHBPA/SSO/SSAT criteria were included in the forest plot
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comparable as the adjuvant therapy trials only included
patients who were able to undergo resection, recovered
well after surgery to undergo chemotherapy, and in
some studies were required to not have metastatic
disease on a postoperative scan [130]. Previous studies
have suggested that only approximately 50–60% of the
patients are able to receive adjuvant therapy after sur-
gery [16–18]. In the current study, resectable patients
who were able to undergo resection after neoadjuvant
therapy had a median OS of up to 30 months. Median
survival among those patients with resectable tumors
who were unable to undergo resection for various
reasons was only 10 months. It can be speculated that
these patients might not have benefitted from upfront
resection and might have developed rapidly progressive
disease in the postoperative period. Conversely, NAT
could have precluded these patients from undergoing a
curative resection. Although adjuvant therapy can add
some incremental prolongation of survival, surgery
remains the only curative-intent treatment option. At
this time upfront surgery followed by a combination of
gemcitabine and capecitabine remains the standard of
care for resectable pancreatic adenocarcinoma based on
the results of ESPAC-4 trial [135]. In this phase 3, open
label, randomized controlled trial median OS of patients
in the gemcitabine plus capecitabine arm was 28 months
compared to 25.5 months for gemcitabine alone (HR
0.82, 95% CI 0.68–0.98, p = 0.032. Neoadjuvant therapy
for resectable pancreatic adenocarcinoma remains an
area of active investigation. One of the ongoing trials
S1505 conducted by Southwest Oncology Group (A
randomized phase II study of perioperative mFOLFIRI-
NOX vs. gemcitabine/nab-paclitaxel as therapy for
resectable pancreatic adenocarcinoma, clinicaltrials.gov
NCT02562716) is evaluating the role of newer multidrug
regimens in neoadjuvant setting, in patients with
resectable pancreatic adenocarcinoma, with a primary
endpoint of OS. Such studies will shed further light on
the effectiveness of neoadjuvant therapy in resectable
pancreatic adenocarcinoma [136]. Additionally, all
attempts should be made to study NAT in resectable
pancreatic cancer in the context of clinical studies.
The role of neoadjuvant therapy in patients with
borderline resectable pancreatic adenocarcinoma is well
recognized [7]. Interestingly, for patients with locally
advanced disease, 22% were eventually able to achieve
an R0 resection in the current review. R0 resection rates
were 82% in patients who underwent resection. A recent
Fig. 6 Forest plots depicting pooled estimates for progressive disease at the time of restaging during or after neoadjuvant therapy. Only studies
utilizing NCCN or AHBPA/SSO/SSAT criteria were included in the forest plot
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meta-analysis based on FOLFIRINOX for locally ad-
vanced pancreatic cancer reported a similar resection
rate of 25.9% and R0 resection rate of 78.4% [137]. As
more effective chemotherapeutic regimens become
available, more patients may be able to undergo resection
and may experience improvement in OS. One such study
(clinicaltrials.gov NCT 02839343, Alliance 021501) is in-
vestigating the role of pre-operative extended chemother-
apy (mFOLFIRINOX pre-operatively and FOLFOX post-
operatively) with or without hypofractionated radiation
therapy in patients with borderline resectable pancreatic
adenocarcinoma.
Our study has several limitations given the heterogeneity
among studies, heterogeneity in the regimens, use of radi-
ation in some studies, and varying duration and tolerability
of treatments—however, this is an expected and inherent
feature of any systematic review. Heterogeneity between
the patient populations, chemotherapy regimens, etc. could
account for wide confidence intervals for some of the
reported outcomes. The lack of standardization in the
surgical techniques and pathologic assessment of speci-
mens also makes comparison across studies challenging.
Ideally, a meta-analysis should be performed using individ-
ual patient data; however, individual patient data may not
always be available or practical. Although meta-analysis
may be superior to individual studies, its qualitative results
need to be viewed carefully even when the analysis is
performed on data quantitatively larger than single-
institutional studies. An extensive forward and backward
search was undertaken to ensure the completeness of litera-
ture along with abstracts of selected meetings. However,
there is a possibility that some studies might have been
missed.
In addition, although the consensus guidelines at-
tempt to separate patients into three distinct
categories (R, BR and LA), in practice there can be
some overlap between the BR and LA categories. At
the extremes of BR and LA, the distinction is well-
characterized, but there are several patients where the
distinction is not that obvious (for example patients
with approximately 180 degree involvement of SMA).
Thus, some of the comparisons in the studies
between the different categories need to be interpreted
with caution. It also needs to be borne in mind that the
adoption of FOLFIRINOX and gemcitabine-nab paclitaxel
regimens is relatively recent (2011 and 2013) with lack of
robust randomized controlled data. Our study used the
Evans criteria for pooling the estimates of pathologic
response [138]. Although Evans criteria remain the most
widely used pathologic criteria for response assessment,
Table 4 Surgical exploration and resection rates after neoadjuvant therapy
Surgical treatment Explored/N Resected/N R0/N Resected/explored R0/resected
Resectable 86% 76% 63% 92% 88%
[79–92%] [68–84%] [51–75%] [85–97%] [80–94%]
I2 = 83.91% I2 = 86.02% I2 = 90.69% I2 = 83.37% I2 = 81.82%
(n = 18) (n = 18) (n = 14) (n = 18) (n = 14)
Borderline resectable 77% 69% 54% 91% 84%
[66–86%] [59–78%] [37–71%] [84–96%] [67–96%]
I2 = 87.62% I2 = 88.98% I2 = 95.15% I2 = 70.68% I2 = 93.75%
(n = 15) (n = 18) (n = 16) (n = 15) (n = 16)
Locally advanced 32% 26% 23% 86% 82%
[23–42%] [19–34%] [15–33%] [73–95%] [69–93%]
I2 = 91.44% I2 = 89.42% I2 = 91.18% I2 = 86.04% I2 = 82.75%
(n = 22) (n = 24) (n = 18) (n = 19) (n = 15)
BR + LA 65% 53% 39% 89% 85%
[49–79%] [36–70%] [27–52%] [80–96%] [79–90%]
I2 = 95.67% I2 = 96.04% I2 = 92.74% I2 = 85.80% I2 = 35.55%
(n = 20) (n = 22) (n = 20) (n = 19) (n = 19)
All patients 64% 55% 45% 91% 85%
[57% -71%] [48–62%] [38–52%] [87–94%] [80–89%]
I2 = 95.27% I2 = 95.34% I2 = 94.94% I2 = 84.53% I2 = 85.05%
(n = 84) (n = 90) (n = 74) (n = 79) (n = 70)
Values in [] reflect the 95% confidence interval. I2 is a quantitative indicator of heterogeneity among the studies, n refers to the number of studies reporting
the outcomes
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these are not universally adopted [139]. Given the limita-
tions of the current study, we could not perform a head to
head comparison of morbidity and mortality of surgery
followed by adjuvant therapy vs neoadjuvant therapy
followed by surgery. Finally, the radiologic response rates
may vary with the use of radiation therapy and also type of
radiation therapy, i.e., IMRT vs SBRT. Response after che-
moradiation may have different biological relevance than
response after systemic chemotherapy alone. We could not
decipher the effect of radiation given the differences in the
duration, doses, and type of radiation treatments. In spite
of its limitations, the current study provides a comprehen-
sive summary of the data on neoadjuvant therapy for
pancreatic adenocarcinoma and these data can be used for
counseling at the time of informed consent for those
patients interested in neoadjuvant therapy.
Conclusions
In conclusion, the current study reviewed data on 5520
patients with pancreatic adenocarcinoma (all stages of
all non-metastatic disease: resectable, borderline resect-
able, and locally advanced) treated with neoadjuvant
therapy and published in the last 7 years. The data
summarize the surgical treatment, radiologic response,
toxicity, pathologic response, morbidity and mortality as
well survival of patients with pancreatic adenocarcinoma
treated with neoadjuvant therapy. Although surgery first
continues to be the standard of care and the only
curative-intent treatment option for resectable disease,
the results of this systematic review demonstrate
increasing adoption of neoadjuvant therapy with some
favorable outcomes. The introduction of more effective
chemotherapeutic agents will help in increasing the
Fig. 7 Forest plot depicting pooled estimates for resection rates after neoadjuvant therapy. Only studies utilizing NCCN or AHBPA/SSO/SSAT
criteria were included in the forest plot
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acceptance of neoadjuvant therapy in certain subpopula-
tions. Ongoing therapeutic/clinical trials to test, validate
and introduce newer and more effective chemotherapeu-
tic agents will go a long way in tackling this lethal
disease for which we may have reached the peak of our
surgical expertise.
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Table 5 Summary of Median Overall Survivals in the various studies included in the current review
Overall survival (months)
All patients Resected Not resected
Resectable Median (range) 18.2 (13–28) 30.0 (24.5–46) 10 (9–11)
n 9 8 5
Borderline resectable Median (range) 19.2 (9.1–45) 27.4 (19.3–41.2) 12.9 (9–15.5)
n 11 8 7
Locally advanced Median (range) 13.6 (7.3–32.5) 18.7 (14.4–24.9) 12.6 (8–19.7)
n 28 8 7
BR + LA Median (range) 14.7 (10.6–47.2) 26 (13–47.4) 12.4 (8.8–17)
n 16 11 9
All patients Median (range) 15.3 (7.3–47.2) 24.4 (11.7–47.4) 11.5 (5.7–19.7)
n 63 39 32
Progression-free survival (months)
All patients Resected Not resected
Resectable Median (range) 8.4 (6.2–10.4) 14.9 (8.4–23) 11*
n 2 4 1
Borderline resectable Median (range) 9 (2.4–21.1) 15.4 (4.7–23.2) 2.1*
n 6 6 1
Locally advanced Median (range) 9.3 (4–17.6) 12.9 (9.6–22.5) 5.7 (4–8)
n 20 6 3
BR + LA Median (range) 9.9 (6.5–27.4) 12.5 (9–19.7) 7.5 (7.1–7.6)
n 9 4 2
All patients Median (range) 9.3 (2.4–27.4) 12.9 (4.7–23.2) 5.8 (2.1–11)
n 31 20 7
*Only one observation. n number of studies reporting the outcome. Values in parenthesis indicate ranges
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